Skip to main navigation

Search for:

Search

Rubius Therapeutics

About Us
Our Science
Our Pipeline
- Pipeline Overview
- Therapeutic Areas
Investors & Media
Careers
Contact

Menu Search

Press Releases

Year

March 25, 2019

Rubius Therapeutics Appoints Natalie Holles to its Board of Directors and Greg Whitehead as Senior Vice President and Chief Quality Officer

March 19, 2019

Rubius Therapeutics to Announce Fourth Quarter and Full-Year 2018 Financial Results

March 11, 2019

Rubius Therapeutics Announces FDA Clearance of Investigational New Drug Application for First-Ever Red Cell Therapeutic, RTX-134, for Treatment of Phenylketonuria

February 27, 2019

Rubius Therapeutics Announces Poster Presentations at the 2019 American Association for Cancer Research Annual Meeting

February 19, 2019

Rubius Therapeutics to Participate at Upcoming Investor Conferences

January 7, 2019

Rubius Therapeutics Highlights Upcoming 2019 Milestones at the 37th Annual J.P. Morgan Healthcare Conference

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 11 - 16 of 16

Print Page

RSS Feeds

Share Page

Email Alerts

Contact Us

399 Binney St, Suite 300
Cambridge, MA 02139 617-679-9600

Share

LinkedIn Twitter

Home
About Us
Our Science
Our Pipeline
Investors
Careers
Sitemap
Terms of Use
Privacy Policy

© Rubius Therapeutics, Inc. 2019. All Rights Reserved. RUBIUS and RED PLATFORM are registered trademarks of Rubius Therapeutics, Inc. RUBIUS THERAPEUTICS, RED CELL THERAPEUTICS and RCT are trademarks of Rubius Therapeutics, Inc. All other trademarks referenced herein are the properties of their respective owners.

Facebook
Twitter
LinkedIn